Gross profit in 1HFY2024 also decreased by 8.50% y-o-y, mainly due to an increase in the cost of inventories, consumables and surgery expenses.
Despite the revenue drop, the company’s fair value gains on financial assets of $0.8 million in 1HFY2024 compared to its fair value losses of $0.9 million in 1HFY2023 contributed to its earnings increase.
HCSS holds a direct interest in Medinex , Singapore Paincare Holdings and Aoxin, shareholdings of 22.66%, 2.44% and 0.34%, respectively.
As at Nov 30, the company’s cash and cash equivalents stood at $6.5 million.
See also: Keppel Pacific Oak US REIT’s 1QFY2025 distributable income falls by 19.3% y-o-y to US$9.6 mil
An interim dividend of 0.7 cents per ordinary share has been recommended for 1HFY2024, payable on March 13.
Shares in HCSS closed unchanged at 30 cents on Jan 11.
